PXRB (PixarBio) Debt-to-Equity : 0.00 (As of Sep. 2016)

View and export this data going back to 2016. Start your Free Trial

What is PixarBio Debt-to-Equity?

PixarBio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $0.00 Mil. PixarBio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $0.00 Mil. PixarBio's Total Stockholders Equity for the quarter that ended in Sep. 2016 was $0.36 Mil. PixarBio's debt to equity for the quarter that ended in Sep. 2016 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for PixarBio's Debt-to-Equity or its related term are showing as below:

PXRB's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

PixarBio Debt-to-Equity Historical Data

The historical data trend for PixarBio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Debt-to-Equity Chart

PixarBio Annual Data

Trend

Dec14

Dec15

Debt-to-Equity

PixarBio Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Debt-to-Equity	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of PixarBio's Debt-to-Equity

For the Biotechnology subindustry, PixarBio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PixarBio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PixarBio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where PixarBio's Debt-to-Equity falls into.

PixarBio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

PixarBio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0.278
	=	0.00

PixarBio's Debt to Equity Ratio for the quarter that ended in Sep. 2016 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0.357
	=	0.00

PixarBio (GREY:PXRB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

PixarBio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of PixarBio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

PixarBio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155

Website

https://www.pixarbio.com

PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.